Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biontech
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Rabies
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03713086 |
CV-7202-104 | P1 |
Completed |
Rabies |
2021-11-23 |
34% |
2024-12-20 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/10/2020 |
News Article |
CureVac Announces Proposed Initial Public Offering of Common Shares |
|
01/07/2020 |
News Article |
CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study |